MannKind | MNKD - Выручка от реализации





Продажи Изменить Дата
Adma Biologics USD 139.16M 4.94M 2025-12
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Insmed USD 263.8M 121.8M 2025-12
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
MannKind USD 111.96M 29.83M 2025-12
Merck USD 16.4B 880M 2025-12
Minerva Neurosciences USD 0 0 2024-09
Novavax USD 147.14M 76.69M 2025-12
Novo Nordisk DKK 12.53B 560M 2025-12
Pfizer USD 17.58B 880M 2025-12
Sanofi EUR 11.24B 60M 2026-03
Xencor USD 28.24M 7.24M 2025-12